Voyager Therapeutics
VYGR
112 hedge funds and large institutions have $103M invested in Voyager Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 35 reducing their positions, and 18 closing their positions.
62% more call options, than puts
Call options by funds: $120K | Put options by funds: $74K
6% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 35
2.96% less ownership
Funds ownership: 62.91% → 59.95% (-3%)
3% less funds holding
Funds holding: 116 → 112 (-4)
12% less capital invested
Capital invested by funds: $117M → $103M (-$14.3M)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.6M |
| 2 |
BlackRock
New York
|
+$1.03M |
| 3 |
Renaissance Technologies
New York
|
+$877K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$856K |
| 5 |
VPC
Vestal Point Capital
New York
|
+$728K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.99M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.12M |
| 3 |
AC
Armistice Capital
New York
|
-$2.05M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$856K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$684K |
VYGR Hedge Fund Activity: Q2 2025 in Review
112 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2025, worth a combined $103M — down 12% from $117M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VYGR and 14 opened new positions — a net loss of 4 holders — while 35 trimmed existing stakes and 33 added.
The largest buyer was Millennium Management, adding an estimated $2.6M. The largest seller was Farallon Capital Management, cutting an estimated $5.99M.
- 112 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2025, down from 116 in Q1 2025.
- Funds reported $103M of Voyager Therapeutics stock for Q2 2025, down 12% quarter-over-quarter.
- 14 funds opened new Voyager Therapeutics positions in Q2 2025 and 18 closed out, a net change of -4 holders.
- The largest Voyager Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $2.6M added.
- The largest Voyager Therapeutics seller in Q2 2025 was Farallon Capital Management, an estimated $5.99M sold.
Based on aggregated 13F filings for Q2 2025.